Veroshpilactone, capsules 100 mg 30 pcs
€8.47 €7.41
Spironolactone is an aldosterone antagonist that competitively binds to aldosterone receptors in the distal renal tubules.
Aldosterone acts as a potassium-saving diuretic by increasing the amount of sodium and water excreted from the body while delaying potassium and magnesium excretion.
The diuretic effect usually develops on days 2-5 of treatment and persists for 2-3 days after discontinuation of the drug.
Indications
Edema syndrome in chronic heart failure, liver cirrhosis (especially with the simultaneous presence of hypokalemia and hyperaldosteronism), nephrotic syndrome;
essential hypertension in adults;
ascites;
diagnosis and treatment of primary hyperaldosteronism (Conn’s syndrome);
prevention of hypokalemia during treatment with saluretics and in patients receiving cardiac glycosides, myasthenia gravis (adjuvant).
Pharmacological effect
Spironolactone, an aldosterone antagonist, competitively binds to aldosterone receptors in the distal renal tubules.
Aldosterone acts as a potassium-sparing diuretic by increasing the amount of sodium and water excreted from the body while delaying the release of potassium and magnesium.
The diuretic effect usually develops on the 2-5th day of treatment and persists for 2-3 days after discontinuation of the drug.
Active ingredient
Spironolactone
Composition
1 tablet contains:
Active substance:
spironolactone 100 mg.
Contraindications
Hypersensitivity, Addison’s disease, acute or rapidly progressive renal failure, chronic renal failure with a significant decrease in excretory function (Cl creatinine less than 10 ml/min), anuria, hyperkalemia, hyponatremia, hypercalcemia.
With caution: Decreased renal excretory function, impaired liver function (increased sensitivity to changes in electrolyte balance), diabetes mellitus (especially diabetic nephropathy), predisposition to metabolic acidosis (acidosis increases the hyperkalemic effect of spironolactone, spironolactone may contribute to the development of acidosis), menstrual irregularities and/or enlarged mammary glands, AV block (possibly increased due to with the development of hyperkalemia).
Side Effects
From the nervous system and sensory organs: dizziness, drowsiness, lethargy, lethargy, headache, ataxia, confusion.
From the gastrointestinal tract: nausea, vomiting, diarrhea, cramps, intestinal colic, gastritis, ulceration and bleeding in the gastrointestinal tract, impaired liver function.
From the genitourinary system: gynecomastia (usually reversible, in rare cases may persist after drug withdrawal), pain in the mammary glands, erectile dysfunction in men, decreased potency in men, menstrual irregularities or amenorrhea, metrorrhagia during menopause, hirsutism, voice changes in women.
From the skin: maculopapular or erythematous skin rashes, alopecia, hypertrichosis, itching, urticaria.
Other: calf muscle cramps, benign breast tumors, chest pain, leukopenia (including agranulocytosis), thrombocytopenia, electrolyte imbalance, hyperkalemia, increased blood urea nitrogen, creatinine, osteomalacia, drug fever.
Interaction
Pharmacodynamic interaction
Verospilactone reduces the sensitivity of blood vessels to norepinephrine. This must be taken into account when performing general and local anesthesia in patients taking Verospilactone.
Concomitant use of potassium-sparing diuretics with indomethacin or ACE inhibitors leads to the development of hyperkalemia. In combination with other diuretics and antihypertensive drugs, Verospilactone enhances their effect. Therefore, when adding Verospilactone to the treatment regimen, the dosage of such drugs should be reduced.
Pharmacokinetic interaction
Spironolactone has been shown to increase T1/2 of digoxin. This can lead to an increase in the concentration of digoxin in the blood, up to a toxic level, therefore, when taking them together, it is necessary to reduce the dose or increase the interval between doses of digoxin.
Acetylsalicylic acid weakens the diuretic effect of spironolactone by blocking the secretion of the main metabolite, canrenone, in the renal tubules. Indomethacin and mefanamic acid have been shown to inhibit the excretion of canrenone.
Spironolactone enhances the metabolism of antipyrine.
Overdose
Symptoms: nausea, vomiting, drowsiness, confusion, skin rash, diarrhea. Possible electrolyte imbalance and dehydration.
Treatment: Verospilactone should be stopped immediately, induce vomiting and rinse the stomach.
There is no specific antidote. Dehydration, electrolyte disturbances, and hypotension should be treated symptomatically.
Elimination of hyperkalemia is achieved by rapid administration of glucose (20-50% solutions) and insulin at the rate of 0.25-0.5 IU of insulin per 1 g of glucose.
Potassium-sparing diuretics and ion exchange resins are used.
Shelf life
2 years
Manufacturer
Alium JSC, Russia
Shelf life | 2 years |
---|---|
Manufacturer | Alium JSC, Russia |
Medication form | capsules |
Brand | Alium JSC |
Other forms…
Related products
Buy Veroshpilactone, capsules 100 mg 30 pcs with delivery to USA, UK, Europe and over 120 other countries.